Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
A88 | Ann:Change of Director's Interests - Chee Seng Cho | 20/09/24 | 0 | 91 | |||
|
|||||||
A88 | Ann:HY Report for the half-year ended 30 June 2024 (Price Sensitive) | 13/09/24 | 0 | 104 | |||
|
|||||||
A88 | Ann:Results of Meeting | 30/05/24 | 0 | 194 | |||
|
|||||||
A88 | Ann:Chairman's address | 29/05/24 | 0 | 209 | |||
|
|||||||
A88 | Ann:Letter of Intent with UTEM (Price Sensitive) | 23/05/24 | 0 | 238 | |||
|
|||||||
A88 | Ann:Annual General Meeting | 19/04/24 | 0 | 276 | |||
|
|||||||
A88 | Ann:CTO Appointment | 08/04/24 | 0 | 285 | |||
|
|||||||
A88 | Ann:AdvanceTC enters into agreement (Price Sensitive) | 03/04/24 | 0 | 382 | |||
|
See All Discussions
Timeline
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
View More |